Finding: There were no between-group differences in trial-related gallstone complications (40 patients [8%] of 529 in usual care  vs  38 [7%] of 536 in restrictive strategy; p=0·16) and surgical complications (74 [21%] of 358  vs  88 [22%] of 404, p=0·77), or in non-trial-related serious adverse events (27 [5%] of 529  vs  29 [5%] of 526).
Certainty (1-5): 6